Tumor neoantigens are unique mutated proteins in cancer cells. They act like an alarm system, alerting the immune system that cancer cells are a threat. By identifying and characterizing neoantigens, researchers can develop personalized tumor vaccines to help the immune system recognize and attack cancer cells.
The results suggest that both the structural and physical features of neoantigens could play important roles in predicting which ones could be used in cancer vaccines against tumors. The findings were published in the Journal for ImmunoTherapy of Cancer.
"One of the challenges in creating tumor-based cancer vaccines is finding the right mix of neoantigens to elicit a T cell response that can destroy a tumor," said senior author Dr. Karen Taraszka Hastings, professor and chair of the Department of Dermatology at the University of Arizona College of Medicine - Phoenix and a member of the U of A Cancer Center. "We want to find ways to make it easier to choose the right neoantigens to include in cancer vaccines, especially in cancers like cutaneous squamous cell carcinoma and melanoma that contain a high number of mutations."
Tumor vaccines can include dozens of mutated tumor protein fragments, or peptides. Some experimental vaccines aimed against mutations in a person’s tumor already exist, including for melanoma and pancreatic and non-small cell lung cancers. But for some cancers, such as cutaneous squamous cell carcinoma, there are thousands of tumor peptide mutations and no good way to figure out which mutations will be most useful in a vaccine.
The researchers found both human and mouse cancers have a high number of mutations, including the same key mutations that are instrumental in causing tumors. Using a mouse model, they also identified two neoantigens that prompted T cells to halt tumor growth.
Both of the neoantigens caused T cells to produce a strong anti-tumor response, while the normal version of the peptides did not. When they looked closer, they saw that each of the neoantigens worked differently though both were equally visible to the immune system.
Before T cells can act against tumor neoantigens, the immune system has to recognize them. The neoantigens must first attach to the major histocompatibility complex, or MHC, a set of proteins that act as a display case.
The team discovered that the MHC displayed the mutated Picalm peptide, whereas it didn’t display the normal peptide. This is likely responsible for the ability of mutated Picalm peptide to stimulate an anti-tumor T cell response. In contrast, the mutated Kars peptide and the normal peptide were bound to the MHC in similar ways.
"So, there is a different reason that mutated Kars elicits a T cell response that destroyed the tumor," Hastings said.
To find out why, the scientists turned to 3D, artificial intelligence-based modeling to look for differences in the structures of the peptides and how they connected to the MHC.
"We found that the mutated Kars peptide has a different chemical structure on the surface of the 3D structure that is exposed to the T cell receptor," Hastings said. "It is likely that this difference in the peptide structure between mutated and normal Kars is recognized by the T cell receptor, which results in a response that restricts tumor growth in mice."
They examined all known cancer neoantigens that have been tested individually for the ability to control tumor growth and found that increased exposure of the mutated peptide to the T cell receptor was key.
"We are proposing 3D structural modeling as a way to further narrow down which neoantigens to select for inclusion in cancer vaccines, which should improve their effectiveness," she said.
Hastings believes 3D modeling may be especially important for predicting useful neoantigens for developing individualized vaccines against skin cancers and melanoma, and it could have applications for other types of cancer as well. The team plans to test their ideas on human tumor samples next.
"The use of artificial intelligence in developing a new approach to building personalized cancer vaccines speaks to the transformative nature of the technology for cancer therapeutics," said David Ebert, chief AI and data science officer at the U of A. "Dr. Hastings’ research is a perfect example of the potential impact of the University of Arizona on the future of medicine and patient care."
Adams AC, Macy AM, Borden ES, Herrmann LM, Brambley CA, Sonar SA, Ma T, Li X, Hughes A, Roe DJ, Mangold AR, Nikolich JZ, Buetow KH, Wilson MA, Baker BM, Hastings KT.
Structural changes from wild-type define tumor-rejecting neoantigens.
J Immunother Cancer. 2025 Oct 22;13(10):e013148. doi: 10.1136/jitc-2025-013148